Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-849-4 | CAS number: 100-41-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Administrative data
- Endpoint:
- one-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study methodology followed was according to OECD TG 415 and in accordance with the Principles of GLP
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 415 [One-Generation Reproduction Toxicity Study (before 9 October 2017)]
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Ethylbenzene
- EC Number:
- 202-849-4
- EC Name:
- Ethylbenzene
- Cas Number:
- 100-41-4
- Molecular formula:
- C8H10
- IUPAC Name:
- ethylbenzene
- Details on test material:
- No data
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Age at study initiation: approximately 11 weeks
- Weight at study initiation: males - 341-406 g, females - 225-273 g
- Fasting period before study: no
- Housing: individually housed in suspended wire mesh cages
- Diet (e.g. ad libitum): Certified Rodent Lab Diet 5002 (PMI Nutrition International Inc.), ad libitum except during exposure
- Water (e.g. ad libitum): reverse osmosis-treated tap water, ad libitum except during exposure
- Acclimation period: 16 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): controlled to 71 ± 5 ºF
- Humidity (%): 50 ± 20% relative humidity
- Air changes (per hr): 10 air changes/hour
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle
Administration / exposure
- Route of administration:
- other: inhalation exposure 6 hours/day; gavage thrice daily at 2 hour intervals
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: Vehicle: conditioned air for inhalation exposure, corn oil for oral exposure.
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Rats were exposed in 2 m3 stainless steel and glass whole-body inhalation chambers
- Method of holding animals in test chamber: not specified
- Source and rate of air: not specified
- Method of conditioning air: not specified
- System of generating particulates/aerosols: not specified
- Temperature, humidity, pressure in air chamber: not specified
- Air flow rate: not specified
- Air change rate: not specified
- Method of particle size determination: not specified
- Treatment of exhaust air: not specified
TEST ATMOSPHERE
- Brief description of analytical method used: GC
- Samples taken from breathing zone: not specified
- Monitoring of test atmosphere: Concentrations of ethylbenzene in the inhalation chambers were measured at least 10 times per exposure day by an automatic sampling system coupled to a gas chromatograph
PREPARATION OF DOSING SOLUTIONS: not specified
The inhalation/gavage females received the vehicle, corn oil, or the test article in the vehicle via oral gavage at a constant dose volume of 1 mL/kg for gavage exposure. An aliquot from each formulation was taken on the first day of dose administration and once during the gavage exposures and analyzed by GC. Stability was determined over 10 days (room temperature
VEHICLE
- Justification for use and choice of vehicle (if other than water): corn oil, (divided into 3 equal doses, approximately 2 hours apart)
- Concentration in vehicle: not specified
- Amount of vehicle (if gavage): constant dose volume of 1 mL/kg
- Lot/batch no. (if required): not specified
- Purity: not specified - Details on mating procedure:
- - M/F ratio per cage: 1:1 (male:female)
- Length of cohabitation: 2 weeks
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0] of pregnancy
- Further matings after two unsuccessful attempts: [no]
- After successful mating each pregnant female was caged: individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Inhalation
0, 100, 500 and 1000 ppm
Actual mean exposure concentrations achieved in the chambers were:
F0 (P) generation 99, 500, and 1008 ethylbenzene.
F1 generation 101, 498, and 1002 ethylbenzene
Gavage
0, 90, 342 and 621 mg/kg
Dosing formulations were analyzed demonstrating the formulations were homogeneous and stable (up to 10 days).
Results of periodic concentration analyses returned the following mean concentration ranges (mg/L):
Target Actual
30 29.9 - 33.7
114 112 - 122
207 205 - 231 - Duration of treatment / exposure:
- Inhalation + gavage on lactation days 1-4 for half of the dams.
F0 (P) Daily, 6 hour-exposures. Males were exposed to test atmospheres for a minimum of 4 weeks. Females were exposed for a minimum of 2 weeks prior to mating, throughout the mating period, and from gestation day 0 through gestation day 20. At this time, one-half of the F0 females were selected for the inhalation/gavage phase and the remaining females selected for the inhalation phase only.
Inhalation only LD1-4: exposure of the F0 females was suspended from gestation day 21 through lactation day 4.
Oral gavage LD1-4: The inhalation/gavage females received the vehicle, corn oil, or the test substance in the vehicle via oral gavage. (divided into 3 equal doses, approximately 2 hours apart)
Post LD4: Inhalation exposure of the F0 females in both phases was re-initiated on lactation day 5 and continued through the day prior to euthanasia
F1 - The F1 offspring were potentially exposed to the test subtance in utero and through nursing during lactation until weaning. On lactation days 21 and 28, pups were weaned and selected (one pup/sex/litter) for inhalation exposure to the same concentration of the test subtance as their dam beginning on postnatal day 22 or 29 and lasting through postnatal day 33 - Frequency of treatment:
- daily
- Details on study schedule:
- - F0 parental animals not mated until 13 weeks
- Selection from F1 generation when pups were [21/28] days of age.
- Weight at mating of the animals in the study: males [339-443 g], females [222-301 g]
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0 ppm (inhalation) and 0 mg/kgt (oral by gavage)
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
100 ppm (inhalation) and 90 mg/kg (30 mg/l - oral by gavage)
Basis:
analytical conc.
99 and 101 ppm (P and F1 generation - inhalation) and 29.9-33.7 mg/l (oral by gavage)
- Remarks:
- Doses / Concentrations:
500 ppm (inhalation) and 342 mg/kg (114 mg/l - oral by gavage)
Basis:
analytical conc.
500 and 498 ppm (P and F1 generation - inhalation) and 112-122 mg/l (oral by gavage)
- Remarks:
- Doses / Concentrations:
1000 ppm (inhalation) and 621 mg/kg (207 mg/l - oral by gavage)
Basis:
analytical conc.
1008 and 1002 ppm (P and F1 generation - inhalation) and 205-231 mg/l (oral by gavage)
- No. of animals per sex per dose:
- 20 male +20 female/dose
- Control animals:
- yes
- Details on study design:
- No data
- Positive control:
- not applicable
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily (prior to exposure and within 1 hour after completion of each exposure period)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once weekly
BODY WEIGHT: Yes
- Time schedule for examinations: P generation - Male body weight were recorded weekly until euthanasia. Female body weight and feed consumption were recorded weekly until mating, on 8 occasions during gestation (3 day intervals) and 7 occasions during lactation (3-7 day intervals).
FOOD CONSUMPTION: Yes
- Time schedule for examinations: same as above
- Oestrous cyclicity (parental animals):
- None
- Sperm parameters (parental animals):
- None
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: [yes]
- If yes, maximum of [10] pups/litter ([5]/sex/litter as nearly as possible); excess pups were killed and discarded.
PARAMETERS EXAMINED
The following parameters were examined in [F1] offspring:
[number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities]
- Each pup was subject to a detailed physical examination on postnatal days 1, 4, 7, 14, 21 and 28.
- Pup body weights were recorded on postnatal days 1, 4, 7, 14, 21 and 28
- Weaning and selection - Each dam and litter remained housed together until weaning on lactation day 28 except for one pup/sex/litter that was weaned on postnatal day 21. The day following weaning (postnatal day 21 or 28), one male and one female per litter that were randomly selected were directly exposed to the same concentration of the test article as their dam through postnatal day 33. Direct inhalation exposure periods for the selected pups were postnatal days 22-33 (F1 postnatal days 22-33) or postnatal days 29-33 (F1 postnatal day 29-33).
GROSS EXAMINATION OF DEAD PUPS:
[yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead.] - Postmortem examinations (parental animals):
- - Necropsy - Adults P(F0): All parental animals were subject to gross examination at sacrifice which was after mating for males and after weaning for females. Unscheduled deaths were also subject to necropsy. For females that delivered the number of former implantation sites were recorded. For females that failed to deliver, non-gravid uteri were opened and placed in 10% ammonium sulfide solution for detection of implantation sites. Organ weights were recorded for livers and kidneys
- Postmortem examinations (offspring):
- - Necropsy - Pups F1: A gross necropsy was performed on all pups on PND 28 for unselected pups and on PND 34 for pups selected for further toxicity evaluation.
- Statistics:
- Chi-square test with Yates' correction factor: parental mating and fertility indices
Parametric one-way analysis of variance (ANOVA) for homogeneous and normal data or Kruskal-Wallis nonparametric ANOVA for non-homogeneous or non normal data: mean parental (weekly, gestation and lactation) and F2 offspring body weight, food consumption and food efficiency data, organ weight data, maternal estrous cycle data, pre-coital intervals, gestation lengths, implantation sites, unaccounted sites, numbers of pups born, and live litter size.
Kruskal Wallis nonparametric ANOVA: mean litter proportions (percent per litter) of postnatal pup survival, sex ratio at birth (percentage of males per litter.
Nested analysis of covariance (ANCOVA): pup weights through weaning - Reproductive indices:
- Mating Index, Fertility Index, Mean pre-coital interval (days) and gestation length
- Offspring viability indices:
- Live litter size, number of live pups and males/litter (%)
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Other effects:
- not examined
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
Details on results (P0)
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS) - F0 (P) Body weight gain was decreased in the 500 and 1000 ppm group males and females during the first week of exposure (p<0.05 or p<0.01) and continued to be reduced in the 1000 ppm group males during the second week of exposure (not statistically significant). As a result of the reduced body weight gain during the first 2 weeks of exposure, mean body weights in the 1000 ppm group F0 males were reduced 4.2-4.7% during study weeks 2-4 (p<0.05). In the F0 females the reduction was not of sufficient magnitude to produce a reduction in mean body weight relative to control. Body weight parameters were unaffected in the low exposure group.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS) - Ethylbenzene did not adversely affect reproductive performance in either sex.
(results given by dose group: 0, 100, 500, 1000 ppm)
- Mating index (%):
F0 males: 100, 100, 100, 95
F0 females: 100, 100, 100, 95
- Fertility index (%)
F0 males: 75, 85, 100, 95
F0 females: 75, 85, 100, 95
- Mean pre-coital interval (days)
F0: 3.4, 2.7, 3.2, 2.4
- Gestation Length
The mean length of gestation was unaffected by treatment.
F0: 22.1, 21.8, 21.9, 21.8
ORGAN WEIGHTS (PARENTAL ANIMALS) - Organ Weights (F0)
Mean liver (males and females) and kidney (males only) weights were increased in the 500 and 1000 ppm (generally statically significant, p<0.01). Relative liver weights were increased 13.1 and 26.6% in the 500 and 1000 ppm male groups, respectively. Relative kidney weights were increased 10.5 and 19.0% in the same respective groups. In females, relative liver weights were increased 21.9 and 37.6% at 500 and 1000 ppm, respectively, inhalation phase only and 14.0 and 25.8% for these same groups for inhalation/gavage phase (generally statistically significant p<0.05 or p<0.01).
GROSS PATHOLOGY (PARENTAL ANIMALS) - Necropsy Observations
At the scheduled necropsies, no macroscopic findings related to test article exposure were observed at any exposure concentration.
OTHER FINDINGS (PARENTAL ANIMALS) - Implantation sites: The mean number of implantation sites did not differ between the groups:
(by dose group: 0, 100, 500, 1000 ppm)
- F0: 15.9, 15.5, 15.7, 15.5
Effect levels (P0)
- Dose descriptor:
- NOAEC
- Effect level:
- 1 000 ppm
- Sex:
- male/female
- Basis for effect level:
- other: Ethylbenzene at an exposure level of 1000 ppm did not adversely impact reproduction (F0).
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not specified
Details on results (F1)
Postnatal survival was slightly reduced from birth to postnatal day 4 in the 500 and 1000 ppm groups (inhalation phase) and in the 1000 ppm/621 mg/kg bwt/day group (inhalation/gavage phase) compared to concurrent and historical controls:
By dose group: 0/0, 100/90, 500/342, 1000/621 ppm/mg/kg bwt/day
From birth to postnatal day 4 (pre-selection): (%)
- F1 inhalation phase: 99.1, 91.7, 86.5, 84.1* (* not statistically significantly different but lower than concurrent and historical control data and occurred in presence of other adverse effects to pups, hence considered treatment-related)
- F1 Inhalation/gavage phase: 95.1, 97.2, 94.6, 88.7
F1 weanlings exposed from PND 22-33
Several exposure-related deaths were observed in the 500 (1/9M) and 1000 ppm (2/9M) group (inhalation phase) weanlings and the F1 1000 ppm/621 mg/kg bwt/day (inhalation/gavage) phase weanlings (3/9 M and 1/9F). Other deaths occured which were not considered exposure related.
F1 weanlings exposed from PND 29-33
No deaths were noted in the F1 weanlings exposed to ethylbenzene beginning on postnatal day 29 (postnatal days 29-33) at any dose level
CLINICAL SIGNS (OFFSPRING) - F1 weanlings exposed from PND 22-33. Exposure-related clinical signs were observed one hour following exposure to 500 ppm, 1000 ppm or 1000 ppm/621 mg/kg and included labored respiration, eyelids half-closed, prostration, righting difficulty, rocking, lurching, and swaying while ambulating. These findings were generally noted in the first several days of exposure only. No adverse effects were observed on clinical signs in the F1 weanlings exposed to 100 ppm of ethylbenzene alone beginning on postnatal day 22.
F1 weanlings exposed from PND 29-33
No adverse effects were observed on clinical signs in the F1 weanlings exposed either by inhalation only or by inhalation and gavage
BODY WEIGHT (OFFSPRING) - F1 weanlings exposed from PND 22-33
F1 weanlings exposed to 500 and 1000 ppm beginning on postnatal day 22 showed a reduction in mean body weight gain in both the inhalation and inhalation/gavage phases (postnatal days 22-33 animals)(p<0.05 or p<0.01). Reductions in mean body weights ranged from 3-14% in the 500 ppm animals and 9-27% in the 1000 ppm animals. Slightly reduced mean body weights were noted in the F1 weanlings exposed to 100 ppm beginning on postnatal day 22 in both the inhalation (4-14%) and inhalation/gavage (6-16%) phases. The only statistically significant difference(p<0.05) from the control group at 100 ppm was noted on postnatal day 31 for females in the inhalation phase.
F1 weanlings exposed from PND 29-33
These F1 weanlings exhibited reduced mean body weight gain at 500 or 1000 ppm in both the inhalation and inhalation/gavage phases. The differences from the control group were statistically significant (p<0.05 or p<0.01) for the inhalation only animals. At 1000 ppm by postnatal day 34, body weights were reduced by 6-13% and, at 500 ppm by postnatal day 34, body weights were reduced by 5-9%. Mean body weights and body weight gains in the F1 weanlings exposed to 100 ppm of ethylbenzene beginning on postnatal day 29 were similar to control group values.
ORGAN WEIGHTS (OFFSPRING) - no data
GROSS PATHOLOGY (OFFSPRING) - No treatment-related changes were apparent in the pups
OTHER FINDINGS (OFFSPRING)
- LITTER DATA
No statistically significant differences were present in litter parameters. Combined Phase by dose group: 0/0, 100/90, 500/342 and 1000/621 ppm/mg/kg bwt/day
- Live litter size:
F1: 14.2, 14.5, 13.8, 13.7
- No. live pups:
F1: 14.3, 14.7, 14.6, 14.4
Males/litter (%):
F1: 48.5, 48.1, 46, 49
- Pup body weight:
Pup weight reductions occurred in the 1000 ppm inhalation exposure groups and were more pronounced in the inhalation/gavage phase (14.8 and 10.9% in male and female pups, respectively, on postnatal day 28)(p<0.05 or p<0.01) than in the inhalation phase (3.4 and 4.3% in the male and female pups, respectively, on postnatal day 28) during the pre-weaning period. These results suggest that at the top dose level the gavage dosing of the dams on lactation days 1 to 4 affected the growth of the offspring
Effect levels (F1)
- Dose descriptor:
- NOEC
- Generation:
- F1
- Effect level:
- 100 ppm
- Sex:
- male/female
- Basis for effect level:
- other: Based on evidence of reduced weight gain at 500 ppm and 1000 ppm in the F0 generation and on reduced pup survival (F1) through lactation, reductions in pup weights at 1000 ppm and to a lesser extent at 500 ppm
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
None
Applicant's summary and conclusion
- Conclusions:
- Ethylbenzene at an exposure level of 1000 ppm did not adversely impact reproduction (F0). Based on evidence of reduced weight gain at 500 ppm and 1000 ppm in the F0 generation and on reduced pup survival (F1) through lactation, reductions in pup weights at 1000 ppm and to a lesser extent at 500 ppm. These effects were observed with and without gavage administration on PND's 1-4.
Clinical signs of toxicity and reduced survival and reduction in bodyweight gain were observed only in the F1 generation exposed from PND 22 particularly at the top dose level and to a lesser extent at 500 ppm. - Executive summary:
In this pilot study, 20 male and 20 female Sprague Dawley rats (P/F0 generation) were exposed via the inhalation route to vapors of ethylbenzene at levels of 100, 500 and 1000 ppm (6 hours/day); males exposed for a minimum of 4 weeks and females exposed to a minimum of 2 weeks prior to mating and via oral by gavage route at dose levels of 90, 342 and 621 mg/kg (divided into 3 equal doses, approximately 2 hours apart).
Analytical verification of the doses indicated a good agreement between the nominal and analytical concentrations.
Animals were paired on a 1:1 basis after treatment for at least 2 weeks. Each pair was examined daily and mating was confirmed by the presence of a copulatory plug or presence of sperm in a vaginal smear (assigned gestation day 0).
Parameters observed were clinical signs, body weights, food consumption, litter observation and pathology (gross). Oestrous cyclicity and sperm examinations were not performed during the study.
Ethylbenzene did not adversely affect reproductive performance in either sex and the mean length of gestation was unaffected by treatment.
The mean number of implantation sites did not differ between the groups.
At the scheduled necropsies, no macroscopic findings related to test article exposure were observed at any exposure concentration.
Mean liver (males and females) and kidney (males only) weights were increased in the 500 and 1000 ppm (generally statically significant, p<0.01). Relative liver weights were increased 13.1 and 26.6% in the 500 and 1000 ppm male groups, respectively. Relative kidney weights were increased 10.5 and 19.0% in the same respective groups. In females, relative liver weights were increased 21.9 and 37.6% at 500 and 1000 ppm, respectively, inhalation phase only and 14.0 and 25.8% for these same groups for inhalation/gavage phase (generally statistically significant p<0.05 or p<0.01).
F1 generation - Postnatal survival was slightly reduced from birth to postnatal day 4 in the 500 and 1000 ppm groups (inhalation phase) and in the 1000 ppm/621 mg/kg bwt/day group (inhalation/gavage phase) compared to concurrent and historical controls.
Several exposure-related deaths were observed in the 500 (1/9M) and 1000 ppm (2/9M) group (inhalation phase) weanlings and the F1 1000 ppm/621 mg/kg bwt/day (inhalation/gavage) phase weanlings (3/9 M and 1/9F) during postnatal days 22-23.
No deaths were noted in the F1 weanlings exposed to ethylbenzene beginning on postnatal day 29 (postnatal days 29-33) at any dose level.
F1 weanlings exposed from PND 22-33. Exposure-related clinical signs were observed one hour following exposure to 500 ppm, 1000 ppm or 1000 ppm/621 mg/kg and included labored respiration, eyelids half-closed, prostration, righting difficulty, rocking, lurching, and swaying while ambulating. These findings were generally noted in the first several days of exposure only. No adverse effects were observed on clinical signs in the F1 weanlings exposed to 100 ppm of ethylbenzene alone beginning on postnatal day 22.
F1 weanlings exposed from PND 29-33
No adverse effects were observed on clinical signs in the F1 weanlings exposed either by inhalation only or by inhalation and gavage.
F1 weanlings exposed to 500 and 1000 ppm beginning on postnatal day 22 showed a reduction in mean body weight gain in both the inhalation and inhalation/gavage phases (postnatal days 22-33 animals)(p<0.05 or p<0.01). Reductions in mean body weights ranged from 3-14% in the 500 ppm animals and 9-27% in the 1000 ppm animals. Slightly reduced mean body weights were noted in the F1 weanlings exposed to 100 ppm beginning on postnatal day 22 in both the inhalation (4-14%) and inhalation/gavage (6-16%) phases. The only statistically significant difference(p<0.05) from the control group at 100 ppm was noted on postnatal day 31 for females in the inhalation phase.
F1 weanlings exposed from PND 29-33
These F1 weanlings exhibited reduced mean body weight gain at 500 or 1000 ppm in both the inhalation and inhalation/gavage phases. The differences from the control group were statistically significant (p<0.05 or p<0.01) for the inhalation only animals. At 1000 ppm by postnatal day 34, body weights were reduced by 6-13% and, at 500 ppm by postnatal day 34, body weights were reduced by 5-9%. Mean body weights and body weight gains in the F1 weanlings exposed to 100 ppm of ethylbenzene beginning on postnatal day 29 were similar to control group values.No statistically significant differences were present in litter parameters observed.
Pup weight reductions occurred in the 1000 ppm inhalation exposure groups and were more pronounced in the inhalation/gavage phase (14.8 and 10.9% in male and female pups, respectively, on postnatal day 28) (p<0.05 or p<0.01) than in the inhalation phase (3.4 and 4.3% in the male and female pups, respectively, on postnatal day 28) during the pre-weaning period.
No treatment-related changes were apparent in the pups at necropsy.
Based on the results of the study, Ethylbenzene at an exposure level of 1000 ppm did not adversely impact reproduction (F0) and was considered as NOAEL for the P/F0 generation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)